Hanmi Pharmaceutical's Efeglenatide Receives Fast Track Designation for Obesity Treatment in South Korea
核心洞察
Hanmi Pharmaceutical's obesity drug Efeglenatide (搜索) has been designated for South Korea's Global Innovative Product Fast Track (GIFT) program, reducing review timelines by approximately 25%.
Phase 3 trial results in 448 adult obese patients showed up to 30% weight loss with Efeglenatide (搜索) demonstrating superior efficacy and favorable safety profile compared to existing GLP-1 (搜索) agents.
The company plans to submit approval applications within this year based on 40-week safety and efficacy data, with commercialization targeted for the second half of next year.
Hanmi Pharmaceutical's in-house developed obesity drug Efeglenatide (搜索) has received fast track designation from South Korea's Ministry of Food and Drug Safety, positioning the company for accelerated regulatory approval and potential market entry in the competitive GLP-1 (搜索) obesity treatment space.
The Ministry of Food and Drug Safety designated Efeglenatide (搜索) as a candidate for the Global Innovative Product Fast Track (GIFT) program on November 27, 2024. This designation qualifies Efeglenatide as an "innovative new drug developed by an innovative pharmaceutical company" for obesity treatment, enabling priority review with dedicated screening teams and customized evaluation processes.
Regulatory Advantages and Timeline Acceleration
The GIFT program, operational since September 2022, supports development of innovative medical products in Korea by accelerating review processes for treatments that either lack existing alternatives or demonstrate significant medical improvement potential. According to the Ministry of Food and Drug Safety, GIFT designation reduces review timelines by approximately 25% compared to standard approval processes.
Products qualify for GIFT designation by meeting specific criteria including absence of existing treatment options, significant efficacy improvements, enhanced safety profiles, or development by innovative pharmaceutical companies. The expedited review system aims to accelerate market launch of breakthrough therapies through various benefits including assignment of dedicated review teams and priority screening.
Phase 3 Clinical Trial Results
In October 2024, Hanmi Pharmaceutical announced topline results from the 40-week core treatment period of Efeglenatide (搜索)'s phase 3 trial involving 448 adult obese patients without diabetes. The study demonstrated significant weight reduction efficacy with favorable safety characteristics compared to existing GLP-1 (搜索) agents.
At week 40, patients receiving Efeglenatide (搜索) achieved an average weight reduction of 9.75%, showing significant superiority over the placebo group. The treatment demonstrated particularly strong efficacy in female patients with BMI under 30 kg/m², who experienced an average weight reduction of 12.20%. Maximum weight reduction reached 30.14% in this patient subgroup, representing the most prominent therapeutic effect observed in the trial.
Safety Profile and Metabolic Benefits
Data analysis revealed that Efeglenatide (搜索) demonstrated strong competitive advantages with a favorable safety profile, as the incidence of gastrointestinal adverse events was either lower or milder compared to existing GLP-1 (搜索) agents. This safety advantage could enhance medication convenience and treatment adherence for long-term obesity management.
Secondary endpoints including BMI, waist circumference, glucose levels, lipid markers, and blood pressure showed significant improvements in the Efeglenatide (搜索) group compared to placebo, confirming comprehensive metabolic benefits beyond weight reduction.
Extended Study and Approval Timeline
Hanmi Pharmaceutical is currently conducting a 24-week extension study to evaluate the durability of weight loss effects over a total treatment period of 64 weeks. Based on safety and efficacy results demonstrated through week 40, the company plans to submit approval applications within 2024.
Kim Nayoung, Executive Vice President and Head of New Product Development at Hanmi Pharmaceutical, emphasized the clinical significance of the drug's safety profile: "If a drug has fewer side effects, it enhances medication convenience and treatment adherence, making it advantageous for long-term management. Efeglenatide (搜索) has few side effects and can comprehensively manage metabolic diseases, so we expect it to provide a new treatment option not only for obese patients but also for those with diabetes and high metabolic risk."
Commercialization Strategy
Park Jae-hyun, CEO of Hanmi Pharmaceutical, outlined the company's commercialization timeline: "As Efeglenatide (搜索) was selected as a rapid review item by the Ministry of Food and Drug Safety and the possibility of early approval has been secured, we are one step closer to commercialization as a 'national obesity drug'. We will also push ahead with the goal of applying for permission within the year without any problems and accelerate the entire process so that we can meet the new obesity drug in Korea and the United States as soon as possible in the second half of next year."
The GIFT designation positions Efeglenatide (搜索) for potential market entry in South Korea's obesity treatment landscape, with the company targeting commercialization in both Korean and U.S. markets by the second half of 2025.